Intervention Review

Role of chemotherapy additional to high-dose methotrexate for primary central nervous system lymphoma (PCNSL)

  1. Nicole Bergner1,
  2. Ina Monsef1,
  3. Gerald Illerhaus2,
  4. Andreas Engert1,
  5. Nicole Skoetz1,*

Editorial Group: Cochrane Haematological Malignancies Group

Published Online: 14 NOV 2012

Assessed as up-to-date: 31 MAY 2012

DOI: 10.1002/14651858.CD009355.pub2


How to Cite

Bergner N, Monsef I, Illerhaus G, Engert A, Skoetz N. Role of chemotherapy additional to high-dose methotrexate for primary central nervous system lymphoma (PCNSL). Cochrane Database of Systematic Reviews 2012, Issue 11. Art. No.: CD009355. DOI: 10.1002/14651858.CD009355.pub2.

Author Information

  1. 1

    University Hospital of Cologne, Cochrane Haematological Malignancies Group, Department I of Internal Medicine, Cologne, Germany

  2. 2

    University Hospital of Freiburg, Department I of Internal Medicine, Freiburg, Germany

*Nicole Skoetz, Cochrane Haematological Malignancies Group, Department I of Internal Medicine, University Hospital of Cologne, Cologne, Germany. nicole.skoetz@uk-koeln.de.

Publication History

  1. Publication Status: New
  2. Published Online: 14 NOV 2012

SEARCH

  1. Current Version

    Role of chemotherapy additional to high-dose methotrexate for primary central nervous system lymphoma (PCNSL)

    Nicole Bergner, Ina Monsef, Gerald Illerhaus, Andreas Engert and Nicole Skoetz

    Article first published online: 14 NOV 2012 | DOI: 10.1002/14651858.CD009355.pub2

Previous versions of this article and their online publication dates

  1. Version 1

    Role of chemotherapy additional to high-dose methotrexate for primary central nervous system lymphoma (PCNSL)

    Nicole Bergner, Sabine Kluge, Ina Monsef, Gerald Illerhaus, Andreas Engert and Nicole Skoetz

    Article first published online: 5 OCT 2011 | DOI: 10.1002/14651858.CD009355